Elfabrio Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

elfabrio

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry sjúkdómur - Önnur meltingarvegi og efnaskipti vörur, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).